Most of the allogeneic transplants performed at our and other institutions involve matched donors. Despite HLA-matching, graft-versus-host-disease (GVHD) still occurs in 50% of these cases. Attempts have been made at our own institution to combat GVHD by removing T cells from the donor graft prior to transplant. This T cell depletion (TCD), although reducing the severity of GVHD, has increased the frequency of graft rejection. In this proposal, we intend to utilize our expertise in murine transplant models to construct a murine model of TCD-induced graft rejection across minor histocompatability barriers. We will use these models to evaluate immunotoxins as potential agents for overcoming graft rejection. Immunotoxins (IT) are monoclonal antibodies (moab) linked to potent catalytic toxins such as ricin toxin A chain (RTA) and are designed to deliver a lethal hit to specific antigen expressing target cells. These agents are currently under clinical evaluation for GVHD therapy at our and other institutions.
Our specific aims are to test the hypothesis that RTA IT administered in vivo will promote engraftment across the minor histocompatibility barrier. Since in vivo attempts to define the role of immune cells in the recognition of minor histocompatibility antigens have been hampered by the unavailability of agents that can reliably and selectively deplete target cell populations, we intend to use our experience with RTA IT to define the cell populations involved in the engraftment network. Various RTA IT will be studied for in vitro selectivity and potency and then studied in vivo. We will determine optimal conjugation conditions, dosage, route, and schedule for each IT. Efficacy of engraftment promotion will be measured in both short-term and long-term engraftment systems. In vivo depletion of target cells will be monitored using fluorochrome labeled moab and flow cytometry and function. We also intend to test the hypothesis that the presence of the translocation-enhancing regions of toxin makes better IT. Many catalytic toxins such as ricin and pseudomonas exotoxin A (PE) have an enhancing region that promotes translocation of the A chain into target cells. This region is separate from the native binding site that renders these toxins dangerous to man. The state of the art now permits us to produce recombinant toxin devoid of the native binding region, but containing the toxic A chain and the translocation enhancing region. In this proposal we will study such a toxin, called PE40, as an IT in our BMT model, PE40IT will be studied and compared to RTA IT.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA021737-19
Application #
5206952
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
19
Fiscal Year
1996
Total Cost
Indirect Cost
Flynn, Catherine M; Hirsch, Betsy; Defor, Todd et al. (2007) Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol 82:867-72
Orchard, Paul J; Blazar, Bruce R; Wagner, John et al. (2007) Hematopoietic cell therapy for metabolic disease. J Pediatr 151:340-6
Grewal, Satkiran S; Barker, Juliet N; Davies, Stella M et al. (2003) Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood 101:4233-44
Wagner, John E; Barker, Juliet N; DeFor, Todd E et al. (2002) Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100:1611-8
Sladek, Norman E (2002) Leukemic cell insensitivity to cyclophosphamide and other oxazaphosphorines mediated by aldehyde dehydrogenase(s). Cancer Treat Res 112:161-75
Browne, P V; Weisdorf, D J; DeFor, T et al. (2000) Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 26:865-9
Delforge, M; Boogaerts, M A; McGlave, P B et al. (1999) BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal. Blood 93:284-92
Warwick, A B; Mertens, A C; Shu, X O et al. (1998) Outcomes following mechanical ventilation in children undergoing bone marrow transplantation. Bone Marrow Transplant 22:787-94
Katsanis, E; Weisdorf, D J; Miller, J S (1998) Activated peripheral blood mononuclear cells from patients receiving subcutaneous interleukin-2 following autologous stem cell transplantation prolong survival of SCID mice bearing human lymphoma. Bone Marrow Transplant 22:185-91
Arns da Cunha, C; Weisdorf, D; Shu, X O et al. (1998) Early gram-positive bacteremia in BMT recipients: impact of three different approaches to antimicrobial prophylaxis. Bone Marrow Transplant 21:173-80

Showing the most recent 10 out of 416 publications